No abstract available
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Algorithms
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine
-
Chemotherapy, Adjuvant
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Digestive System Neoplasms / drug therapy*
-
Disease Progression
-
Drug Administration Schedule
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / adverse effects
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Interferon-alpha / administration & dosage
-
Intestinal Neoplasms / drug therapy
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Neuroendocrine Tumors / drug therapy*
-
Neuroendocrine Tumors / mortality
-
Neuroendocrine Tumors / pathology
-
Octreotide / administration & dosage
-
Octreotide / adverse effects
-
Octreotide / therapeutic use*
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Thoracic Neoplasms / drug therapy*
-
Time Factors
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Gastrointestinal Agents
-
Interferon-alpha
-
Organoplatinum Compounds
-
Oxaliplatin
-
Deoxycytidine
-
Capecitabine
-
Octreotide
-
Fluorouracil